Wegovy Cost: Insurance and Savings

Wegovy (semaglutide 2.4 mg) has a list price of approximately $1,349.02 per month for a 4-week supply. That number applies at every dose level during titration and at the maintenance dose. Whether you actually pay that amount, a fraction of it, or nothing out of pocket depends on a chain of variables: your insurance plan, your deductible status, prior authorization outcomes, manufacturer savings programs, and whether compounded alternatives are on the table.

The pricing landscape for GLP-1 medications is complicated and changes frequently. Here's where things stand and what your options are.

The List Price vs. What People Actually Pay

The $1,350 figure is the wholesale acquisition cost (WAC) — the price Novo Nordisk charges distributors. It's the number that makes headlines and the number uninsured patients see at the pharmacy counter. But most people don't pay list price.

With commercial insurance + savings card: Some patients pay $0-$25 per fill after insurance and the Novo Nordisk savings program are applied. This is the best-case scenario and requires commercial insurance that covers Wegovy.

With commercial insurance, no savings card: Copays typically range from $25-$300 per month depending on the plan's formulary tier, coinsurance structure, and whether the deductible has been met.

With commercial insurance that doesn't cover Wegovy: You're back to approximately $1,350 per month out of pocket, or you can use the savings card for a reduced price (typically capping out-of-pocket at $500/month for a limited number of fills, though terms change).

Medicare Part D: Weight loss medications are explicitly excluded from Medicare Part D coverage. This is a statutory exclusion, not an insurer decision. Legislation to change this has been introduced in Congress but had not passed as of early 2026. Medicare patients pay full price or use alternatives.

Medicaid: Coverage varies by state. Some state Medicaid programs cover Wegovy, some cover it with restrictions, and many do not cover it at all. Check your state's formulary.

Uninsured: Full list price applies. Novo Nordisk's patient assistance programs may offer help for qualifying low-income patients, but eligibility requirements are strict.

Insurance Coverage: How to Navigate It

Prior Authorization

Nearly every insurance plan that covers Wegovy requires prior authorization (PA). This means your prescriber must submit documentation to the insurer proving medical necessity before the pharmacy can fill the prescription.

Typical PA requirements include:

• BMI documentation: BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Failed lifestyle modification: Some insurers require documented evidence that diet and exercise alone were insufficient, often requiring 3-6 months of documented effort
• No contraindications: Confirmation that you don't have MEN2, personal/family history of medullary thyroid carcinoma, or other contraindications
• Prescriber type: Some plans require the prescription to come from an endocrinologist or obesity medicine specialist rather than a primary care physician

The PA process typically takes 3-14 business days. If denied, you have the right to appeal. Your prescriber's office usually handles the initial PA submission, but following up on status and managing appeals may require your involvement.

Step Therapy Requirements

Some insurers impose step therapy — they require you to try and fail on cheaper weight loss medications before they'll cover Wegovy. Common required steps include phentermine/topiramate (Qsymia), naltrexone/bupropion (Contrave), or liraglutide (Saxenda). You may need documented evidence of insufficient response or intolerable side effects on these agents before the insurer will authorize Wegovy.

Formulary Tier

When covered, Wegovy typically sits on a specialty tier (Tier 4 or 5), which means higher cost-sharing than generic medications. Specialty tier coinsurance rates of 20-30% on a $1,350 medication can still leave you with $270-$405 per month before any savings card is applied.

Novo Nordisk Savings Programs

Wegovy Savings Card

Novo Nordisk offers a manufacturer savings card for Wegovy. Current terms (which change periodically):

• Eligible patients: Those with commercial (private) insurance. Government-insured patients (Medicare, Medicaid, Tricare, VA) are excluded.
• Benefit: Reduces out-of-pocket copay or coinsurance, potentially to $0 per fill.
• Duration: Covers up to 13 four-week supplies (approximately one year of treatment).
• How to enroll: Through the Wegovy website or by calling the number on the site. Your prescriber's office may also enroll you.

The savings card interacts with your insurance benefit — it pays the portion that insurance doesn't cover, up to the program's maximum. If your insurance doesn't cover Wegovy at all, the savings card may still reduce the price, but typically to a higher amount ($500/month range) rather than $0.

Patient Assistance Programs

For uninsured or underinsured patients who meet income requirements, Novo Nordisk offers patient assistance through programs like NovoCare. These may provide Wegovy at no cost for qualifying patients. Income thresholds and documentation requirements apply.

Compounded Semaglutide: The Cheaper Alternative

Compounded semaglutide has emerged as a significantly lower-cost alternative to branded Wegovy and Ozempic. Compounding pharmacies produce semaglutide preparations — typically for injection — at prices ranging from $150-$500 per month depending on the pharmacy, dose, and whether it's bundled with a telehealth consultation.

Why It's Cheaper

Compounding pharmacies purchase semaglutide as a bulk ingredient and formulate it into injectable preparations, bypassing the branded product's pricing structure. During the FDA-declared shortage period for semaglutide products, compounding pharmacies were permitted to compound copies of commercially available drugs under Section 503A and 503B of the FD&C Act.

FDA Concerns

The FDA has raised specific safety concerns about compounded semaglutide products:

Semaglutide sodium salt vs. semaglutide base: Some compounding pharmacies have used semaglutide sodium, a salt form that is not the same molecular entity as the semaglutide base used in Ozempic and Wegovy. The FDA has questioned whether semaglutide sodium has the same safety and efficacy profile, and whether doses are equivalent.

Sterility and purity: Compounded medications are not subject to the same manufacturing standards as FDA-approved drugs. Reports of adverse events from compounded GLP-1 products have been filed with the FDA, including dosing errors and contamination concerns.

Shortage status: The legality of compounding copies of semaglutide products is tied to FDA shortage declarations. If semaglutide is no longer in shortage, compounding pharmacies may be required to stop producing copies. The regulatory status of this question has been actively debated and litigated.

If You're Considering Compounded Semaglutide

• Discuss it with your prescriber. They should know what you're taking and from where.
• Verify the compounding pharmacy is licensed and registered (503A or 503B facility).
• Ask for certificates of analysis showing purity and potency testing.
• Understand that adverse events from compounded products may not be systematically tracked the way branded product events are.
• Be aware that the dose you're getting may not be directly comparable to branded Wegovy doses if a different salt form is used.

Other Cost-Reduction Strategies

Ozempic for Weight Loss (Off-Label)

Ozempic contains the same active ingredient (semaglutide) as Wegovy but is FDA-approved for type 2 diabetes, not weight management. Some patients with type 2 diabetes receive Ozempic, which may be covered under their plan's diabetes formulary at lower cost-sharing than Wegovy on the obesity formulary. This is a prescriber decision based on your clinical situation — it's not a loophole to exploit, and insurance companies are increasingly auditing off-label use.

Flexible Spending and Health Savings Accounts

If Wegovy is prescribed and you have an FSA or HSA, the out-of-pocket cost after insurance is generally an eligible expense. This doesn't reduce the price, but it lets you pay with pre-tax dollars, effectively reducing your cost by your marginal tax rate.

Manufacturer Coupons and Seasonal Offers

Novo Nordisk periodically runs promotional programs beyond the standard savings card. Check the Wegovy website and ask your prescriber's office about current offers.

What the Cost Discussion Misses

The sticker price conversation often omits the cost of not treating obesity. Weight-related comorbidities — type 2 diabetes, hypertension, sleep apnea, joint degeneration — carry their own substantial costs in medications, procedures, lost productivity, and reduced quality of life. The Institute for Clinical and Economic Review (ICER) has evaluated semaglutide for obesity and, while finding the list price exceeds certain value benchmarks, acknowledged the clinical benefit is significant.

This doesn't make $1,350/month affordable for people who can't pay it. But it's worth understanding that the cost-benefit calculation extends beyond the monthly pharmacy bill.

Tracking Your Costs Alongside Your Treatment

When you're managing a medication with variable monthly costs — insurance changes, savings card renewals, pharmacy switches — tracking the financial side alongside your dose and side effect data helps you make informed decisions about your treatment plan.

Done Dose logs your injection dates and doses, which gives you a record of exactly how many fills you've used (relevant for savings card limits), how long you've been on treatment, and whether your titration schedule is on track. When it's time to renew your prior authorization or evaluate whether Wegovy is sustainable in your budget, having accurate treatment data makes those conversations with your prescriber and insurer more productive.

Summary of Cost Paths

The number you pay depends on which row you're in. Start by checking your insurance formulary, apply for the savings card regardless, and have a direct conversation with your prescriber about alternatives if the out-of-pocket cost is a barrier. Affordability is a legitimate clinical consideration, and any good prescriber will work with you on it.